Covid Drug Molecule GRL0617 Assay with HPLC - AppNote
December 27, 2022
/
/
/
/
Date: 27-DECEMBER-2022 Last Updated: 11-SEPTEMBER-2026
GRL-0617, a benzamide anti-Covid molecule and potent non-covalent inhibitor
This simple gradient analyzing GRL-0617 is easily performed, and the 5 injections overlay below demonstrates run to run consistency and great peak symmetry. The peak efficiency is very good, peak tailing is minimal, and repeatability is easily met with RSD values being less than 1.0%.
Peak: GRL0617
Met hod Conditions:Column: Cogent RP Phenyl Hexyl™, 5 um, 100 Å
Catalog No.: 68539-15P
Dimensions: 4.6 mm x 150 mm
Mobile phase:
-- A: DI water and 0.1% formic acid
-- B: Acetonitrile and 0.1% formic acid
Gradient:
| time (minutes) | %B |
|---|---|
| 0 | 25 |
| 1 | 25 |
| 5 | 85 |
| 6 | 85 |
| 8 | 25 |
| 10 | 25 |
Flow rate: 1.0 mL/minute
Injection volume: 1 μL
Detection: UV @ 224 nm
Sample Preparation: 1.0 mg/mL of GRL-0617 i n methanol.
%RSD: <0.5%, t0: 2.0 minutes, K’: 2.075
Note 1: GRL0617 is an inhibitor of SARS-CoV and SARS-CoV-2 papain-like proteases (PL-pro) . It is selective for the viral proteases over human proteases. GRL0617 blocks both PL-pro-mediated actions towards host biological processes and virus replication.
Note 2: Capacity is determined using the following equation: k = (tR-t0)/tO
- tR = Retention Time of an Analyte Peak
- tO = Retention Time of non-Retained Peak
